GlassScriptPhysician profile
Basil Michael Yurcisin
NPI 1003062050
$29,605.09
in general payments reported to CMS, 2019-2025
21 companies · $3,703 in 2025
The $3,703 reported for 2025 was more than what 88% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $577 · 2021: $312 · 2022: $619 · 2023: $2,231 · 2024: $7,230 · 2025: $3,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,624 · Food and Beverage: $4,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,624.40 |
| Food and Beverage | $4,539.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Standard Bariatrics, INC. | $14,905.76 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $7,545.90 | 2019-2025 | Seamguard, Gore Seamguard Bioabsorbable Staple Line Reinforce, Gore Bio-A Tissue Reinforcement |
| Medtronic, INC. | $2,559.15 | 2021-2025 | Ligasure, Signia |
| Medical Device Business Services, INC. | $1,315.53 | 2025 | Linx Reflux Management System |
| Intuitive Surgical, INC. | $874.30 | 2024 | |
| Teleflex LLC | $811.89 | 2023-2025 | Titan Sgs Bailout Chuck, Weck, Titan Sgs |
| Stryker Corporation | $592.01 | 2023 | 1688 |
| Ambu INC. | $261.17 | 2024 | |
| Ethicon US, LLC | $145.45 | 2021-2025 | Linx Reflux Management System |
| Endo Pharmaceuticals INC. | $145.19 | 2019-2024 | Nascobal |
| Covidien LP | $119.24 | 2019 | |
| Phathom Pharmaceuticals, INC. | $76.57 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $45.48 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $38.29 | 2025 | Gattex |
| Lilly USA, LLC | $36.99 | 2025 | Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.74 | 2020-2025 | Wegovy |
| Olympus America INC. | $26.17 | 2024 | Visera Elite II Video System Center |
| Baudax Bio INC. | $20.66 | 2021 | |
| Abbvie INC. | $19.22 | 2025 | |
| Heron Therapeutics, INC. | $16.45 | 2024 | Zynrelef |
| Intra-Sana Laboratories | $15.93 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Yurcisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.